Menu Search
Equities

Acotec Scientific Holdings Ltd

6669:HKG.HS

Acotec Scientific Holdings Ltd

Actions
  • Price (HKD)7.17
  • Today's Change-0.01 / -0.14%
  • Shares traded280.00k
  • 1 Year change-54.39%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Acotec Scientific Holdings Ltd is a China-based interventional medical device company. The Company focuses on interventional treatment of vascular diseases, involving Drug-coated Balloons (DCB) and Percutaneous Transluminal Angioplasty Balloon Catheter (PTA) etc. The Company has established a product portfolio for five major therapeutic areas, including vascular surgery, cardiology, nephrology, neurology and andrology. The Company's business covers China, Asia, Europe and other countries and regions.

  • Revenue in HKD (TTM)512.13m
  • Net income in HKD15.66m
  • Incorporated2020
  • Employees638.00
  • Location
    Acotec Scientific Holdings Ltd4F to 5F, Building 1No. 16, Hongda North Road, Beijing Econoand Technological Development ZoneBEIJING 100176ChinaCHN
  • Websitehttp://www.acotec.cn/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.